dc.contributor.author | Pliarchopoulou, K. | en |
dc.contributor.author | Kalogeras, K. T. | en |
dc.contributor.author | Kronenwett, R. | en |
dc.contributor.author | Wirtz, R. M. | en |
dc.contributor.author | Eleftheraki, A. G. | en |
dc.contributor.author | Batistatou, Anna | en |
dc.contributor.author | Bobos, M. | en |
dc.contributor.author | Soupos, N. | en |
dc.contributor.author | Polychronidou, G. | en |
dc.contributor.author | Gogas, H. | en |
dc.contributor.author | Samantas, E. | en |
dc.contributor.author | Christodoulou, C. | en |
dc.contributor.author | Makatsoris, T. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Pectasides, Dimitrios | en |
dc.contributor.author | Fountzilas, George | en |
dc.creator | Pliarchopoulou, K. | en |
dc.creator | Kalogeras, K. T. | en |
dc.creator | Kronenwett, R. | en |
dc.creator | Wirtz, R. M. | en |
dc.creator | Eleftheraki, A. G. | en |
dc.creator | Batistatou, Anna | en |
dc.creator | Bobos, M. | en |
dc.creator | Soupos, N. | en |
dc.creator | Polychronidou, G. | en |
dc.creator | Gogas, H. | en |
dc.creator | Samantas, E. | en |
dc.creator | Christodoulou, C. | en |
dc.creator | Makatsoris, T. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Pectasides, Dimitrios | en |
dc.creator | Fountzilas, George | en |
dc.date.accessioned | 2018-06-22T09:52:46Z | |
dc.date.available | 2018-06-22T09:52:46Z | |
dc.date.issued | 2013 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41495 | |
dc.description.abstract | Purpose: RACGAP1 is a Rac GTPase-activating protein involved in cell growth regulation, cell transformation and metastasis. The aim of the present study was to explore the prognostic and/or predictive significance of RACGAP1 mRNA expression on disease-free survival (DFS) and overall survival (OS) in high-risk early breast cancer patients and compare it to that of Ki67 protein expression and to the Nottingham prognostic index (NPI). Methods: A total of 595 high-risk breast cancer patients were treated in a two-arm trial evaluating postoperative dose-dense sequential chemotherapy with epirubicin followed by CMF with or without paclitaxel. RNA was extracted from 314 formalin-fixed paraffin-embedded primary tumor tissue samples followed by one-step quantitative RT-PCR for assessing RACGAP1 mRNA expression. Results: High RACGAP1 mRNA expression (above the median) was associated with poor DFS (log-rank, p = 0.002) and OS (p < 0.001). High histological grade, as well as high Ki67 protein expression, was more frequent in the high-expression group of RACGAP1. Results of the Cox multivariate regression analysis revealed that high RACGAP1 mRNA expression independently predicted poor overall survival (Wald's p = 0.008). High Ki67 protein expression was also an adverse prognostic factor for death (p = 0.016), while high NPI score values were not. Conclusions: High RACGAP1 mRNA expression, as assessed by qRT-PCR, was found to be of adverse prognostic significance in high-risk early breast cancer patients treated with dose-dense sequential chemotherapy. The utility of RACGAP1 mRNA expression in patient selection for treatment with aggressive chemotherapy regimens should be further explored and validated in larger cohorts. © 2012 Springer-Verlag Berlin Heidelberg. | en |
dc.language.iso | eng | en |
dc.source | Cancer chemotherapy and pharmacology | en |
dc.subject | Article | en |
dc.subject | Female | en |
dc.subject | Young adult | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast neoplasms | en |
dc.subject | Controlled study | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Regression analysis | en |
dc.subject | Cancer survival | en |
dc.subject | Paclitaxel | en |
dc.subject | Prediction | en |
dc.subject | Priority journal | en |
dc.subject | Quantitative analysis | en |
dc.subject | Retrospective studies | en |
dc.subject | Retrospective study | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Disease-free survival | en |
dc.subject | Drug effect | en |
dc.subject | Human tissue | en |
dc.subject | Prognosis | en |
dc.subject | Disease free survival | en |
dc.subject | Neoplastic | en |
dc.subject | Overall survival | en |
dc.subject | Cancer prognosis | en |
dc.subject | Survival rate | en |
dc.subject | Epirubicin | en |
dc.subject | Risk assessment | en |
dc.subject | Protein expression | en |
dc.subject | Cancer risk | en |
dc.subject | Gene expression regulation | en |
dc.subject | High risk patient | en |
dc.subject | Protein determination | en |
dc.subject | Unclassified drug | en |
dc.subject | Breast cancer | en |
dc.subject | Cancer grading | en |
dc.subject | Histopathology | en |
dc.subject | Oncogene | en |
dc.subject | Survival time | en |
dc.subject | Randomized controlled trial (topic) | en |
dc.subject | Randomized controlled trials as topic | en |
dc.subject | Risk factor | en |
dc.subject | Disease association | en |
dc.subject | Patient selection | en |
dc.subject | Gene expression | en |
dc.subject | Rna | en |
dc.subject | Multivariate analysis | en |
dc.subject | Messenger rna | en |
dc.subject | Reverse transcription polymerase chain reaction | en |
dc.subject | Ki 67 antigen | en |
dc.subject | Early cancer | en |
dc.subject | Scoring system | en |
dc.subject | Proportional hazards models | en |
dc.subject | Prognostic value | en |
dc.subject | Gene function | en |
dc.subject | Messenger | en |
dc.subject | Reverse transcriptase polymerase chain reaction | en |
dc.subject | Gene identification | en |
dc.subject | Gtpase-activating proteins | en |
dc.subject | Guanosine triphosphatase activating protein | en |
dc.subject | Ki-67 antigen | en |
dc.subject | Ki67 | en |
dc.subject | Nottingham prognostic index | en |
dc.subject | Qrt-pcr | en |
dc.subject | Rac gtpase activating protein 1 | en |
dc.subject | Rac gtpase activating protein 1 gene | en |
dc.subject | Racgap1 | en |
dc.title | Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: A study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1007/s00280-012-2002-z | |
dc.description.volume | 71 | |
dc.description.issue | 1 | |
dc.description.startingpage | 245 | |
dc.description.endingpage | 255 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |